Insider Trading Alert - ENTA, CIEN And NGL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 16, 2014, 80 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.26 to $11,203,447.50.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Mellett Paul J, who is Treasurer and CFO at Enanta Pharmaceuticals, sold 10,000 shares at $39.83 on Sept. 16, 2014. Following this transaction, the Treasurer and CFO owned 136,397 shares meaning that the stake was reduced by 6.83% with the 10,000-share transaction.

The shares most recently traded at $39.84, up $0.01, or 0.02% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 40,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 50,000

The average volume for Enanta Pharmaceuticals has been 232,900 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $743.1 million and is part of the health care sector and drugs industry. Shares are up 45.97% year-to-date as of the close of trading on Tuesday.

Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. The company has a P/E ratio of 23.7. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Insider Trading Alert - ENTA, EBIO And PSEC Traded By Insiders

5 Hated Stocks You Should Love

Insider Trading Alert - ENTA, HBI And MOFG Traded By Insiders

Enanta Pharmaceuticals (ENTA) Showing Signs Of Perilous Reversal Today